- Analyst action today: DA Davidson raised its Rivian price target to $15 (Neutral), citing Q3 execution, lower tariff headwinds and the company’s upcoming Autonomy & AI Day. [1]
- Leadership & governance in focus: Rivian’s board last week approved a new 10‑year CEO compensation plan for RJ Scaringe, including options on 36.5M shares at a $15.22 strike with share‑price milestones of $40–$140 and added profit/cash‑flow targets; his base salary doubled to $2M. The filing also detailed a profits‑interest award linked to Rivian’s new robotics spinoff. [2]
- Fresh corporate venture: Rivian spun out Mind Robotics this month—an industrial AI/robotics venture—with about $110M in external seed capital disclosed in Rivian’s 10‑Q; TechCrunch first reported the spinoff. [3]
- Earnings backdrop: One week on from Q3 results, Rivian’s revenue rose ~78% YoY to ~$1.56B, beating estimates as buyers accelerated purchases before EV incentives expired; management also flagged easing tariff costs. Deliveries reached ~13,201 vehicles. [4]
- What’s next: Rivian’s Autonomy & AI Day is set for Dec. 11, 2025 in the Bay Area, where it plans to detail its driver‑assist/AI roadmap ahead of the R2 launch (targeted for 2026). [5]
Market reaction
Rivian shares were $16.41 at 13:40 UTC, up on a five‑day basis after last week’s post‑earnings rally.
- Today’s DA Davidson note keeps a Neutral stance but nudges the target higher to $15 following Q3, noting the company reduced tariff impacts from “a few thousand” per vehicle to “a few hundred” and is teeing up Autonomy & AI Day in December. [6]
- Separately, Resona Asset Management disclosed it grew its Rivian stake by ~7.9% in Q2 (adding 18,652 shares), a smaller but notable institutional flow published this morning. [7]
What happened today (Nov. 11)
1) Street chatter tilts constructive, but measured
DA Davidson’s target hike to $15 frames the near‑term setup as balanced: execution is improving, tariff drag is moderating, and December’s tech showcase could be a catalyst—but the rating remains Neutral pending clearer visibility on margins and the R2 ramp. [8]
2) CEO compensation remains a headline driver
Investors continue to parse Rivian’s Musk‑style incentive blueprint for CEO RJ Scaringe. The package grants 36.5M options at $15.22, vesting against $40–$140 share‑price gates over 10 years plus operating income/cash‑flow milestones; salary rises to $2M. The filing also reveals 1M “profits interest” units in the new Mind Robotics entity tied to Scaringe’s service as chair. [9]
3) Industrial AI push becomes tangible
Rivian’s newly spun‑out Mind Robotics—a separate company in which Rivian is a shareholder—was formed this month with ~$110M of outside seed funding, aimed at industrial/“physical AI” and robotics applications that could feed back into manufacturing efficiency. [10]
The earnings context investors are trading on
- Top‑line beat: Q3 revenue of ~$1.56B (+78% YoY) came in ahead of consensus, aided by a pre‑expiration rush for U.S. EV incentives at quarter‑end. Rivian delivered ~13,201 vehicles. Management also pointed to lower expected tariff costs ahead. [11]
- Capital & partnerships: The Volkswagen JV remains a strategic pillar supporting software architecture and future products, with staged funding milestones through 2027 per prior disclosures. [12]
Product & technology: What to expect next
- Autonomy & AI Day — Dec. 11: Rivian says it will detail its autonomy stack, data flywheel, and compute platform at a Bay Area event on Thursday, Dec. 11, 2025. Expect emphasis on practical, driver‑assist features vs. robotaxis, per recent analyst commentary. [13]
- R2 cadence: The more affordable R2 SUV remains slated for 2026, with the Normal, Illinois plant central to the launch. Investors will watch for updates on cost‑down initiatives and content (e.g., bidirectional charging) as the model approaches SOP. [14]
What it means for RIVN right now
- Setup into December: With shares around $16, the $15 DA Davidson target effectively brackets the tape, reflecting a “show‑me” stance until Dec. 11 (tech day) and further signs that gross margin progress can persist into 2026 when R2 should expand the addressable market. [15]
- Key swing factors to monitor:
- Event execution at Autonomy & AI Day (feature roadmap, on‑car demos, data strategy). [16]
- Unit economics: trajectory of materials, tariff exposure and software‑adjacent monetization following Q3’s beat. [17]
- Capital partners & JV milestones with Volkswagen as software unifies across programs. [18]
- Governance optics around the CEO package and performance gates vs. shareholder outcomes. [19]
By the numbers (snapshot)
- Share price: $16.41 (13:40 UTC).
- 12‑month Street context: Many houses remain Hold‑tilted near term; DA Davidson’s new $15 PT highlights a wait‑and‑see into catalysts. [20]
Editor’s notes & sources
- Today’s new/updated items (Nov. 11, 2025): DA Davidson price‑target change; MarketBeat’s Resona AM position update. [21]
- Recent but still market‑moving: CEO compensation plan details (Reuters, Nov. 7–8); Q3 earnings (Nov. 4). [22]
- Forthcoming catalyst: Rivian Autonomy & AI Day on Dec. 11, 2025. [23]
Sources: Reuters reporting on CEO compensation and Q3 dynamics; Rivian’s newsroom and SEC filings; DA Davidson note via The Fly/TipRanks; MarketWatch earnings wrap; Electrek for event context; MarketBeat 13F activity note. [24]
Disclosure: This article is for informational purposes only and does not constitute investment advice.
References
1. www.tipranks.com, 2. www.reuters.com, 3. www.sec.gov, 4. www.reuters.com, 5. rivian.com, 6. www.tipranks.com, 7. www.marketbeat.com, 8. www.tipranks.com, 9. www.reuters.com, 10. www.sec.gov, 11. www.reuters.com, 12. www.reuters.com, 13. rivian.com, 14. www.reuters.com, 15. www.tipranks.com, 16. rivian.com, 17. www.reuters.com, 18. www.reuters.com, 19. www.reuters.com, 20. www.tipranks.com, 21. www.tipranks.com, 22. www.reuters.com, 23. rivian.com, 24. www.reuters.com
![Quoin Pharmaceuticals (QNRX) Soars After Hitting 4%/5% Topical Rapamycin Targets; Clinical Batches This Quarter, Human Trials 1H 2026 [Nov. 11, 2025]](https://ts2.tech/wp-content/uploads/2025/11/Quoin-Pharmaceuticals-480x384.jpg "Quoin Pharmaceuticals (QNRX) Soars After Hitting 4%/5% Topical Rapamycin Targets; Clinical Batches This Quarter, Human Trials 1H 2026 [Nov. 11, 2025]")
